Abstract: One aspect of the present disclosure is a sheet type mask gel composition including a polyol, a water-soluble thickener, and water, wherein adhesive strength is maintained for a long time, a mask sheet including the same, and a method of manufacturing the mask sheet.

Abstract: Water-soluble refill dose articles for forming a cleanser have a water-soluble film defining a first compartment enclosing a first composition and a second compartment enclosing a second composition, which are individual separate articles or are part of an integral article. The first composition has a rheology modifier, a first surfactant, 10% or less by weight water, 20% or less by weight glycol, and the first surfactant does not activate the rheology modifier. The second compartment has an alkaline substance that when mixed with the first composition and water activates the rheology modifier to increase the viscosity of a resulting cleanser and 10% or less by weight water. When the article is diluted in water at a 1:1 to 1:20 ratio, it produces a cleanser having a viscosity within a range of 2000 cps to 50,000 cps.

Abstract: Cosmetic blending devices for producing a cosmetic liquid from a solid-shell cosmetic ingredient capsule. The cosmetic blending devices include a lid, a base, a blending element configured to blend the capsule, and a drive mechanism configured to actuate the blending element. The cosmetic blending device may include a thermal element configured to change a temperature of the capsule. The thermal element may melt the capsule. The solid-shell cosmetic ingredient capsule comprises a shell defining an enclosed inner volume, and cosmetic material included in the enclosed inner volume. Methods of using the cosmetic blending devices comprise placing the solid-shell cosmetic ingredient capsule into the cosmetic blending device and blending the capsule to produce the cosmetic liquid. Methods of forming the solid-shell cosmetic ingredient capsule comprise forming a portion of the shell, adding the cosmetic material to the portion of the shell, and forming the remaining portion of the shell.

Abstract: The instant disclosure relates to cosmetic compositions that when applied to skin instantaneously and dramatically improve the appearance of the skin. The compositions include volatile hydrocarbon oil; mineral thickening agents; silicone elastomers; and hydrophobic film forming polymers; wherein the weight ratio of the total amount of hydrophobic film forming polymers to the total amount of mineral thickeners (film forming polymers:mineral thickening agent) is 1:1 to 8:1, and the weight ratio of the total amount of silicone elastomer to the total amount of mineral thickener (silicone elastomer:mineral thickening agent) is 1:1 to 5:1. Methods for improving the appearance of skin comprising application of the cosmetic compositions to the skin are also disclosed.

Abstract: A liquid anhydrous composition including (a) at least one water soluble dye, (b) at least one polyol, and (c) a polyglyceryl-10 pentaoleate, (d) at least one volatile oil, wherein the relative mass amount of (a)/(b)/(c) is ranging between 1/0.6/8?(a)/(b)/(c)?1/6/18, and a method for preparing the liquid anhydrous composition.

Abstract: The present invention provides a topical formulation and method of use where the formulation comprises macqui berry or a macqui berry extract containing anthocyanins having a very high oxygen radical absorbance capacity (ORAC). The formulation provides the macqui berry in a stabilized form which includes a glucuronide or glycuronide, a photostabilizing agent, encapsulation, or light- and/or air-blocking packaging.

Abstract: Provided are preparation and use of novel compounds available as main ingredients of a composition for promoting hair growth, wherein the novel compounds are 9-deoxo-31-O-demethyl-prolyl-FK506, 9-deoxo-36,37-dihydro-FK506, 31-O-demethyl-36,37-dihydro-FK506, 9-deoxo-31-O-demethyl-36,37-dihydro-FK506, 9-deoxo-FK520, 31-O-demethyl-FK520, 9-deoxo-31-O-demethyl-FK520, 9-deoxo-FK523, and 9-deoxo-31-O-demethyl-FK523.

Abstract: The present invention includes compositions and methods preventing or reversing the symptoms of aging in a subject in need thereof comprising administering to the subject an amount of a composition comprising pterostilbene, nicotinamide, and optionally vitamin A (retinol), and one or more retinoids effective to prevent or reverse the symptoms of aging.

Abstract: A family of peptides which prevent and/or reduce the signs of skin aging (including chronological and/or environmental aging) and which are useful for skin firming; cosmetic compositions comprising peptides and cosmetic uses and methods of peptides or cosmetic compositions.

Abstract: Injectable compositions and methods of treating skin can help improve hydration, elasticity and/or texture of the skin. The compositions can be based on crosslinked hyaluronic acid matrices made with low molecular weight hyaluronic acids.

Abstract: The present invention concerns a composition for topical application to keratinous material, in particular the skin and/or lips, comprising, in a physiologically acceptable medium, at least one Lactobacillus rhamnosus extract (CNCM I-5313), one of its fractions and/or one of its metabolites and at least one excipient chosen from solvents other than water, UV filters, surfactants, gelling agents, thickeners, fillers, dyes, film-forming polymers, perfumes and the mixtures of same; and the uses thereof, in particular for promoting and/or improving the skin barrier function.

Abstract: Injectable baclofen formulations and methods that are bioequivalent in terms of plasma baclofen exposure to oral dosage forms but with reduced exposure ratios of baclofen to the M1 metabolite.

Abstract: Disclosed are effective fixed dose oral testosterone undecanoate compositions for use in regimens without dose titration and methods for treatment of patients in need of testosterone replacement therapy. Also disclosed are criteria for continuation and discontinuation of such regimens, based on single serum T concentration levels measured at a steady state at predetermined times after initiation of said regimen and at a predetermined number of hours after administration of a morning dose of the regimen.

Abstract: Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an API, a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.

Abstract: Disclosed are cell membrane-derived nanovesicles, a method of preparing the nanovesicles, and a pharmaceutical composition and a diagnostic kit using the nanovesicles. The cell membrane-derived nanovesicles may prevent potential adverse effects because intracellular materials (e.g., genetic materials and cytosolic proteins) unnecessary for delivering therapeutic or diagnostic substances are removed from the nanovesicles. In addition, as the nanovesicles may be targeted to specific cells or tissues, therapeutic or diagnostic substances may be predominantly delivered to the targeted cells or tissues, while delivery of the substances may be inhibited. Therefore, the nanovesicles may alleviate suffering and inconvenience of patients by reducing adverse effects of therapeutic substances and by improving efficacy of the substances.

Abstract: Methods are provided for treating or preventing human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) in a virologically suppressed patient in need thereof comprising switching the patient from an antiretroviral treatment regimen comprising at least three antiretroviral agents to a treatment regimen comprising only two antiretroviral agents. In one aspect the two treatment regimen consists of dolutegravir, rilpivirine and at least one pharmaceutically acceptable excipient, diluent or carrier. In another aspect of the invention, there is provided a multilayer tablet comprising dolutegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides a lipid nanoparticle for extrahepatic delivery of mRNA, the lipid nanoparticle comprising: (i) mRNA cargo; (ii) a phosphatidylcholine lipid content of from mol % to 70 mol %; (iii) a ionizable, cationic lipid content of from 5 mol % to 50 mol %; (iv) a sterol selected from cholesterol or a derivative thereof; and (v) a hydrophilic polymer-lipid conjugate that is present at a lipid content of 0.5 mol % to 5 mol. Further provided is a lipid nanoparticle preparation comprising lipid nanoparticles having encapsulated mRNA and 20 to mol % of a phosphatidylcholine lipid, an ionizable lipid; and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticles exhibiting at least a 10% increase in gene expression of the mRNA in vivo as measured in one or more extrahepatic organs or tissues. The lipid nanoparticles have an electron dense region and a nitrogen-to-phosphate charge ratio of between 4 and 15.

Abstract: In one aspect, the disclosure relates to compositions, methods, and devices pertaining to polymeric nanoparticle compositions (pNP), pNP compositions comprising a therapeutic agent, devices comprising a drug-coated balloon comprising a disclosed pNP comprising a therapeutic agent, and methods for treating peripheral artery disease using the disclosed compositions and devices. In further aspects, the pNP comprises a poly (lactic-co-glycolic) acid possessing a positive charge for firm attachment to the balloon matrix, followed by adhesion to the negatively charged bilayer of the vascular wall. In still further aspects, the therapeutic agent comprises a resveratrol or derivative thereof, a quercetin or derivative thereof, or combinations thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: The present invention relates to development of a novel cannabinoid-based gold nanoparticle drug delivery system for intravenous or localized administration of cannabinoid drugs. More specifically, the gold nanoparticles with a specific size range are conjugated with various cannabinoid molecules (CBD and THC molecules) to synthesize a stable and biocompatible nano-delivery system suitable for both localized and intravenous administration.

Abstract: Disclosed herein is systems, methods, and apparatuses for treating biological fluids. In some embodiments, the biological fluid treatment system includes a treatment, a platform, an array of light sources, and a display. In some embodiments, the biological fluid treatment system includes a scanner.

Abstract: A lighting fixture containing both visible light sources and UV light sources is disclosed herein. In one embodiment, the fixture is an overhead fixture. UV light can sanitize/disinfect the surrounding environment over a period of about 30-45 minutes. In this way, viruses, germs, bacteria, mold, and the like can be destroyed to clean the air and/or surfaces (e.g., furniture) of the room exposed to UV light. Accordingly, embodiments of the present invention include a physical input device, such as a wall-mounted button, switch, or wireless device, that can safely and efficiently activate a lighting assembly to produce UV light in a way that protects occupants from unintentional exposure to UV light. This configuration is especially useful in situations where the use of UV light is regulated, such as in a hospital setting.

Abstract: A sterilization, disinfection, sanitization, or decontamination system having a chamber defining a region, and a generator for creating a free radical effluent with reactive oxygen, nitrogen, and other species and/or a vaporizer. A closed loop circulating system without a free-radical destroyer is provided for supplying the mixture of free radicals from the generator mixed with the hydrogen peroxide solution in the form of the effluent to the chamber. The system is used in sterilizing, disinfecting, sanitizing, or decontaminating items in the chamber or room and, with a wound chamber, in treating wounds on a body. The wound chamber may be designed to maintain separation from wounds being treated. Various embodiments can control moisture to reduce or avoid unwanted condensation. Some embodiments can be incorporated into an appliance having a closed space, such as a washing machine. Some embodiments may include a residual coating device that deposits a bactericidal coating on sterilized items.

Abstract: A decontamination system employs at least one ozone generator located within an enclosed space, at least one ozone sensor and a control system for controlling the operation of the at least one ozone. During a decontamination cycle, the at least one ozone generator is operated to disperse ozone within the enclosed space until the at least one ozone sensor indicates that a desired decontamination ozone level has been reached.

Abstract: An illuminator comprising more than one set of ultraviolet radiation sources. A first set of ultraviolet radiation sources operate in a wavelength range of approximately 270 nanometers to approximately 290 nanometers. A second set of ultraviolet radiation sources operate in a wavelength range of approximately 380 nanometers to approximately 420 nanometers. The illuminator can also include a set of sensors for acquiring data regarding at least one object to be irradiated by the first and the second set of ultraviolet radiation sources. A control system configured to control and adjust a set of radiation settings for the first and the second set of ultraviolet radiation sources based on the data acquired by the set of sensors.

Abstract: The invention concerns a method of making a synthetic, biodegradable, bone graft comprising a three-dimensional porous structure; a formulation of constituents for use in said method; a synthetic, biodegradable bone graft produced by said method; and a method of surgery comprising use of said bone graft.

Abstract: Foam-based pneumatic actuators can be formed in a state of mechanical compression prior to actuation. An actuator includes an elastomeric foam; a coating disposed on the elastomeric foam; and an elastomer seal disposed on the coating. The coating constrains the elastomeric foam and can be configured to break or fracture when the elastomeric foam inflates. The elastomer seal can be configured to be impermeable to the actuating fluid. Such a foam actuator can be used in a cardiac compression device. These foam actuators possess increased actuation deformation and an actuation exerted force for a given inflation pressure. A large deformation can be provided from materials having low ultimate strains.

Abstract: An antibacterial air freshening product for an interior environment. The product includes a container containing 1 ml to 50 ml of a freshening composition in fluid communication with a membrane. The composition is substantially free of a surfactant and has from 0.5% to 20% of a volatile aldehyde mixture, by weight of the composition. The volatile aldehyde mixture includes a C5 to C8 unbranched unsubstituted linear alkenal and a C9 to C14 unbranched unsubstituted linear alkenal. A weight ratio of the C5 to C8 unbranched unsubstituted linear alkenal to the C9 to C14 unbranched unsubstituted linear alkenal is from 3:1 to 1:3.

Abstract: Electronic imitation candle devices are described that produce a scent while including a flame-like element that simulates a real fire flame. One example device includes a support assembly having a base, a top plate and a support rod that connects the base and the top plate, as well as a flame element and a light source to simulate a real candle flame. The device also includes a fragrance compartment above the top plate that includes a lid removably positioned on top of the fragrance container. The device is further provided with a heating element above the top plate and below the fragrance container to provide heat to the fragrance container, and a switch coupled to the lid of the fragrance container and operable to sense that the fragrance container is covered by the lid and to deactivate the heating element when the fragrance container is covered by the lid.

Abstract: An air scenting system for a vehicle is provided which includes an appliance and a replaceable cartridge installable therein. The replaceable cartridge contains a liquid compound to be aerosolized and has a cartridge outlet through which the aerosolized compound is discharged during operation. A pump is provided to supply air to the replaceable cartridge to generate the aerosolized compound from the liquid compound contained in the replaceable cartridge, and a controller is provided for controlling the pump to supply the air to the replaceable cartridge to generate and discharge the aerosolized compound from the appliance. The appliance is particularly adapted for dispensing scent into the interior space of a vehicle, and includes a form factor particularly well suited for positioning the appliance in a cup holder. Additionally, the appliance is designed for use in vehicles when a driver is present and readily adjustable by the driver to provide a uniform scent experience.

Abstract: Proposed is an indoor quarantine system using an individual mask. The indoor quarantine system may include: an indoor headcount checking device including a headcount checking unit configured to check the number of persons who stay in an indoor space and a headcount providing unit configured to provide headcount information checked by the headcount checking unit to mobile terminals of indoor users; and a disinfection mask worn on an indoor user and activating a disinfection function in accordance with a disinfection command based on the indoor headcount information received from the mobile terminal of the indoor user to disinfect harmful substances around the indoor user.

Abstract: An elevator cab and method of sterilizing the air of an elevator comprising, a plenum configured to fluidly connect to an interior of the elevator cab, at least one intake formed in the side walls of the elevator cab and in fluid communication with the plenum, a fan configured to draw air from the elevator cab via the intake duct and the plenum, and a kill box, including a source of ultraviolet C (UVC) light, and configured to receive air via the fan, wherein the UVC light is configured to sterilize air removed from the elevator cab.

Abstract: Provided are a sterilization module and an air purifier, which are applied in the field of air sterilization. The sterilization module is applied in the air purifier. The sterilization module includes a frame, a plurality of wave-shaped plates, and at least one sterilizing lamp. The frame is provided with a channel running through the frame from one end to another end. The plurality of wave-shaped plates are arranged at intervals in the channel, where each of the plurality of wave-shaped plates is bent alternately from the one end to the another end of the frame, so as to form an air duct that is wave-shaped between two adjacent wave-shaped plates. The at least one sterilizing lamp is disposed on the wave-shaped plate and used to emit ultraviolet (UV) light towards the air duct.

Abstract: A ventilation seat of a vehicle is proposed. The ventilation seat includes a ventilation pipe mounted in a seat of the vehicle and configured to suck indoor air and to discharge air toward a surface of the seat, a catalytic converter provided in an air flow path of the ventilation pipe, and configured to clean air passing through the air flow path when light is emitted, and a light source assembly provided on an inner wall of the air flow path of the ventilation pipe and arranged to face the catalytic converter to emit the light toward the catalytic converter.

Abstract: A platelet agitator includes a base and a frame. The frame moves laterally relative to the base at variable speeds. The agitator further includes a controller and a user interface in communication with the controller. The user interface has a discontinuous input device that has at least a portion of adjustment range that is non-linear compare to the remainder of the adjustment range.

Abstract: A medical fluid delivery system and apparatus for remote machine updating and control are disclosed. An example medical fluid delivery apparatus includes a processor and a dialysis fluid circuit including at least one dialysis fluid pump. The processor determines a dialysis treatment or a preprogrammed task is not being performed by the least one dialysis fluid pump. After determining a dialysis treatment or a preprogrammed task is not being performed, the processor activates a connectivity agent to communicatively couple to a server via a network. The processor then receives, from the server via the connectivity agent, a command message to perform a preprogrammed task. The processor next deactivates the connectivity agent to stop communication with the server and causes the at least one dialysis fluid pump to perform the preprogrammed task.

Abstract: A dialysis system comprising: a dialysis machine; a communication module configured to communicate using a short-range wireless technology protocol; data storage configured to store data corresponding to identities of one or more short-range wireless devices; and a processor configured to: identify presence of a short-range wireless device; and cause the dialysis machine to carry out an action when one or both of i) the presence of the short-range wireless device is identified, and ii) the presence of the short-range wireless device is no longer identified.

Abstract: A peritoneal dialysis system includes a housing; a dialysis fluid pump housed by the housing; a patient line extendable from the housing; and a hose reel located within the housing, the hose reel configured to coil the patient line when disconnected from a patient. The patient line may be a dual lumen patient line, wherein the dual lumen patient line is coiled about the hose reel during a disinfection sequence for disinfecting the dual lumen patient line and the dialysis fluid pump.

Abstract: The invention provides a blood treatment device comprising: a dialyser; an inlet pump assembly; an outlet pump assembly; and a control system. The inlet pump assembly configured to deliver a first volume of dialysate from a dialysate source to the dialyser in an inlet pump cycle having a dialysate delivery stroke. The outlet pump assembly configured to remove a second volume of dialysate from the dialyser and deliver the dialysate away from the dialyser in an outlet pump cycle having a dialysate removal stroke. The control system is configured to operate the inlet pump assembly in the inlet pump cycle, and configured to operate the outlet pump assembly in the outlet pump cycle. For each inlet pump cycle there is a corresponding outlet pump cycle, and each inlet pump assembly dialysate delivery stroke has a commencement time t1 and a termination time h, and each outlet pump assembly dialysate removal stroke has a commencement time t3 and a termination time t4.

Abstract: A dialysis system includes include a home dialysis machine and a home gateway device in communication with a cloud-based application via a connected health system. The gateway device has voice recognition capabilities. A user can provide spoken information to the gateway device, and the gateway device can cause one or more actions to be performed. The gateway device may cause a dialysis function to be performed by the dialysis machine, or data to be input into the dialysis machine. The gateway device can also communicate with one or more other systems (e.g., remote systems) via the cloud-based application. In some examples, the cloud-based application can communicate with an order management system to allow the user to order medical supplies (e.g., for use with the dialysis machine) via the gateway device. The gateway device can provide two-way conversational capability (e.g., back and forth communication) between the user and the gateway device.

Abstract: A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the reservoir for the concentrated red blood cells (RCC) has a first chamber for receiving anticoagulant used for priming the separator and purging the system of air prior to the initial draw cycle and a second chamber for receiving separated red blood cells. Because the entire volume of second chamber of the RCC reservoir may now receive separated red blood cells and no AC prime volume, a greater amount of whole blood may be processed in the first draw cycle, thus resulting in a greater total volume of Immunoglobulin G (IgG) being collected during the plasmapheresis procedure.

Abstract: The present invention relates to a motor-driven suction pump and a method for connecting such a pump. The suction pump has a pump unit for generating a negative pressure which is accommodated in a housing. Further, a terminal box is provided which can be connected to a power source via a connecting cable and has contact elements for supplying the pump unit with a power current. The contact elements are electrically conductively connected to the contact counter elements provided on the housing side and leading to the pump unit when the terminal box is coupled to the housing. In order to increase electrical safety, a sensor, an evaluation unit, and a switch are provided. The sensor is configured to check the coupling of the terminal box. The switch switches a power supply to at least one of the contact elements.

Abstract: A negative pressure wound therapy system can include a negative pressure source configured to provide, via a fluid flow path, negative pressure to a wound covered by a wound dressing. The system can include a controller. The controller can be configured to periodically activate the negative pressure source to maintain negative pressure in the fluid flow path between a low negative pressure setpoint and a high negative pressure setpoint. The controller can be configured to determine a change in a volume of the wound based on a difference between a first time and a second time at which the high negative pressure setpoint has been established in the fluid flow path, the second time being subsequent to the first time. The controller can be configured to provide indication of the change in the volume of the wound.

Abstract: The present application provides a device (100) for transferring a fluid from a surgical site, comprising an elongate body portion (102) defining a proximal end region (106) connectable to a source of negative pressure; an elongate neck portion (104) defining a distal end region (108) of the device locatable at a surgical site; a through bore (118) extending from the distal end region to the proximal end region; and a control member (116) for selectively controlling a negative pressure at the distal end region, wherein the control member comprises a valve portion (124) configured to at least partially restrict a fluid flowing along the through bore when moved from an open position towards a closed position. A system including the device for transferring a fluid from a surgical site is also provided.

Abstract: An electronic smoking article includes an aerosol generator and a mouth end insert. The mouth end insert includes a mechanical aerosol converter surface having the capacity to improve characteristics of aerosol produced by the aerosol generator, including sensory attributes.

Abstract: An electronic device includes a mouthpiece, a bladder, and a mesh assembly having a mesh material and a piezoelectric material. The mesh material is in contact with a liquid of the bladder. The mouthpiece, the bladder, and the mesh assembly are located in-line along a longitudinal axis of the device between opposite longitudinal ends of the device, with the mesh assembly extending between and separating the mouthpiece and the bladder. A liquid-filled cartridge also is disclosed for use with an electronic device for delivery of a substance into a body through respiration includes a liquid container; and a liquid contained within the container for aerosolizing and inhaling by a person using the electronic device. The liquid includes a plurality of nanoparticles in a nanoemulsion, the nanoparticles including the encapsulation of the substance to be delivered into the body through respiration. The nanoemulsion preferably is produced using a microfluidizing machine.

Abstract: Dispensing assembly, comprising a fluid product dispenser, such as a nasal dispenser, wherein the fluid product dispenser comprises a reservoir (10) provided with a bottom (11), a dispensing member (20), such as a pump or a valve, mounted on the reservoir (10), and a dispensing head (30) incorporating a dispensing orifice (31), the dispensing assembly comprising a lateral actuation device comprising a body (1) and a lateral actuation element (40) mounted so as to pivot on the body (1) about a pivot axis (45) between a rest position and an actuation position, the actuation element (40) comprising a bearing part (41), which is pressed by the user during actuation and a pushing part (42) designed to cooperate with the fluid product dispenser to effect the actuation thereof, the pivot axis (45) being arranged between the bearing part (41) and the pushing part (42), the lateral actuation member (40) having an S or inverted S shape, the bearing part (41) being arranged near the dispensing head (30) and the pushing

Abstract: There is disclosed a fluid-transfer article which is suitable for use as part of an aerosol-generating system of a type which may be used as a smoking substitute. The fluid-transfer article comprises a first region for holding an aerosol precursor and for transferring said aerosol precursor to an activation surface of a second region of said article, said activation surface being disposed at an end of said article configured for thermal interaction with a heater of an aerosol-generation apparatus. The activation surface includes at least one arcuate surface portion and is configured such that, when the fluid transfer article is arranged with respect to a said heating surface for thermal interaction therebetween, the or each said arcuate surface portion opposes said heating surface and is concave towards said heating surface.

Abstract: A measurement device and a method for monitoring a condition of a patient. The measurement device includes: a gas-guide apparatus, configured to operatively connect between an medical gas provider and a patient side of the measurement device, and deliver medical gas from the medical gas provider to the patient; and at least one sensing apparatus, placed on an outer surface of the gas-guide apparatus and configured to detect real-time measurement data of the medical gas passing through the gas-guide apparatus. In this way, the at least one sensing apparatus is placed on the outer surface of the gas-guide apparatus, since the measurement data is a relative value which indicates a change of internal environment of the gas-guide apparatus, this can also avoid a problem of contamination compared with setting a sensor inside a respiratory device, thus improving the security of the measurement.

Abstract: An automatic positive airway pressure (AutoPAP) therapy device can be configured such that the minimum and/or maximum pressures deliverable by the device can automatically change. The minimum and/or maximum pressures can change as a function of pressures delivered over the course of the current therapy session and/or over the course of prior therapy sessions. The minimum and/or maximum pressures can also change as a function of the presence, absence, type, severity, or length of sleep disordered breathing events (SDBE) detected by the device over the course of the current therapy session and/or over the course of prior therapy sessions.

Abstract: A full-face mask assembly includes a frame and a cushion provided to the frame. The cushion is adapted to form a seal around the patient's nose and mouth. A flexible lip is provided to an interior wall of the cushion. The flexible lip is adapted to engage the frame to provide a seal in use.